$1.510
0.000 (0.00%)At close
RNAZ Comparative Benchmarking
In the context of the broader market, RNAZ competes directly with industry leaders such as ESLA and PMN. With a market capitalization of $25.56M, it holds a significant position in the sector. When comparing efficiency, RNAZ's gross margin of N/A stands against ESLA's N/A and PMN's N/A. Such benchmarking helps identify whether Transcode Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Transcode Therapeutics Inc Financial Performance
Transcode Therapeutics has shown consistently negative earnings, with a net income loss of -$19,510,296 in Q1 2026 and a gross profit of $0 in Q4 2024, indicating severe financial distress. The current ratio has dropped to 1.97 in Q2 2026, suggesting liquidity issues.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.